Massey, Andrew J <br/><br/>
Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.  [electronic resource] 

 -  Cancer letters  12 2016 
 - 41-52 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1872-7980 
<br/><br/><label>Standard No.: </label>10.1016/j.canlet.2016.09.024  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Apoptosis--drug effects<br/>Ataxia Telangiectasia Mutated Proteins--antagonists & inhibitors<br/>Bone Neoplasms--drug therapy<br/>Cell Proliferation--drug effects<br/>Checkpoint Kinase 1--antagonists & inhibitors<br/>Colorectal Neoplasms--drug therapy<br/>DNA Damage<br/>DNA-Activated Protein Kinase--antagonists & inhibitors<br/>Dose-Response Relationship, Drug<br/>HT29 Cells<br/>Histones--metabolism<br/>Humans<br/>Indoles--pharmacology<br/>Isoxazoles--pharmacology<br/>Molecular Targeted Therapy<br/>Nuclear Proteins--antagonists & inhibitors<br/>Osteosarcoma--drug therapy<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrazines--pharmacology<br/>Pyridones--pharmacology<br/>Signal Transduction--drug effects<br/>Time Factors